NovoCure Ltd. (NVCR)

NASDAQ:
NVCR
| Latest update: Apr 15, 2026, 5:43 PM

Stock events for NovoCure Ltd. (NVCR)

NovoCure's stock price has declined by 32.66% over the past year, underperforming the US Medical Equipment industry and the broader US Market. However, there have been positive developments, including positive topline results from the Phase 2 PANOVA-4 clinical trial for metastatic pancreatic cancer, Optune Lua receiving reimbursement approval in Japan for non-small cell lung cancer, and Optune Pax being approved by the U.S. FDA for locally advanced pancreatic cancer. The company also secured national coverage for Optune Gio in Spain for glioblastoma and received approval for Optune Lua in Japan for NSCLC. Despite these positive milestones, the stock has experienced volatility.

Demand Seasonality affecting NovoCure Ltd.’s stock price

Information detailing demand seasonality for NovoCure Ltd.'s products and services is not available. The company reports active patient numbers and revenue quarterly, indicating consistent operations, but no specific seasonal fluctuations in demand are mentioned.

Overview of NovoCure Ltd.’s business

NovoCure Ltd. is an oncology company focused on extending the survival of patients with aggressive cancers through its Tumor Treating Fields (TTFields) therapy. The company operates in the healthcare sector, specifically in Drug Discovery and Healthcare Equipment & Supplies. NovoCure's platform technology uses electric fields to disrupt the division of solid tumor cancer cells. Its major commercialized products include Optune Gio, approved for glioblastoma; Optune Lua, approved for malignant pleural mesothelioma and metastatic non-small cell lung cancer (NSCLC); and Optune Pax, recently approved for locally advanced pancreatic cancer. NovoCure has a pipeline of products being investigated for various cancers.

NVCR’s Geographic footprint

NovoCure is a global company with operations in North America, Europe, and Asia. Its headquarters are in Baar, Switzerland, with offices in Portsmouth, NH, and New York, NY, in North America; München, Germany, and Boulogne-Billancourt, France, in Europe; and Haifa, Israel, and Tokyo, Japan, in Asia. The majority of its revenue comes from the United States, with significant contributions from Germany, Japan, and other markets. NovoCure also has a strategic partnership with Zai Lab for market access in Greater China.

NVCR Corporate Image Assessment

NovoCure's brand reputation has been positively influenced by its commitment to innovation, patient care, and clinical and regulatory achievements. Its TTFields technology is considered a competitive advantage. Positive clinical trial results from the Phase 2 PANOVA-4 trial, the U.S. FDA approval of Optune Pax for pancreatic cancer, reimbursement approval for Optune Lua in Japan for NSCLC, and securing national coverage for Optune Gio in Spain for glioblastoma have all positively affected its reputation.

Ownership

NovoCure's ownership is a mix of institutional, retail, and individual investors. Institutional Investors own approximately 38.13% to 53.88% of the stock, Insiders own 2.73%, and Public Companies and Individual Investors own 15.75% to 43.39%. Major institutional owners include Fmr Llc, BlackRock, Inc., and Vanguard Group Inc. The largest individual shareholder is William F. Doyle, who owns 22.15% of the company.

Expert AI

Show me the sentiment for NovoCure Ltd.
What's the latest sentiment for NovoCure Ltd.?

Price Chart

$12.28

8.64%
(1 month)

Top Shareholders

FMR LLC
15.07%
BlackRock, Inc.
12.15%
The Vanguard Group, Inc.
9.83%
Soleus GP LLC
7.65%
Morgan Stanley
4.55%
State Street Corp.
2.31%
Geode Holdings Trust
2.22%
Quantinno Capital Management LP
1.80%

Trade Ideas for NVCR

Today

Sentiment for NVCR

News
Social

Buzz Talk for NVCR

Today

Social Media

FAQ

What is the current stock price of NovoCure Ltd.?

As of the latest update, NovoCure Ltd.'s stock is trading at $12.28 per share.

What’s happening with NovoCure Ltd. stock today?

Today, NovoCure Ltd. stock is up by 8.64%, possibly due to news.

What is the market sentiment around NovoCure Ltd. stock?

Current sentiment around NovoCure Ltd. stock is negative, based on recent news, trading volume, and analyst opinions.

Is NovoCure Ltd.'s stock price growing?

Over the past month, NovoCure Ltd.'s stock price has increased by 8.64%.

How can I buy NovoCure Ltd. stock?

You can buy NovoCure Ltd. stock through any brokerage platform, such as e.g., Robinhood, Fidelity, E*TRADE, by searching for the ticker symbol NVCR

Who are the major shareholders of NovoCure Ltd. stock?

Major shareholders of NovoCure Ltd. include institutions such as FMR LLC (15.07%), BlackRock, Inc. (12.15%), The Vanguard Group, Inc. (9.83%) ... , according to the latest filings.